<DOC>
	<DOCNO>NCT02864992</DOCNO>
	<brief_summary>This study look effective study drug ( tepotinib ) stop growth spread lung cancer carry specific genetic alteration ( MET exon 14 skip alteration ) respond standard care treatment chemotherapy ( platinum doublet contain regimen ) . This study also measure number thing include safety study drug side effect , body process study drug , study drug affect quality life . The study also optional pharmacogenetic research part . Pharmacogenetic research important way try understand role genetics human disease gene impact effectiveness drug , difference gene change way person respond particular drug</brief_summary>
	<brief_title>Tepotinib Phase II Study Lung Adenocarcinoma Harbouring MET Exon 14 ( METex14 ) Skipping Alterations</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically confirm advanced adenocarcinoma lung , fail least one bot 2 line systemic therapy , include platinumdoubletcontaining regimen , fail maximum 2 line active therapy MET Exon 14 ( METex14 ) skip alteration , determine central laboratory . Both , archival fresh biopsy acceptable ; In case METex14 skip alteration observe subject pretrial setting , ensure sufficient tissue available retesting trial entry . Only subject METex14 skip mutation base trial central test enrolled trial Signed , write informed consent subject legal representative prior trialspecific screen procedure Male female , great equal ( &gt; = ) 18 year age ( reach age majority accord local law regulation , age majority &gt; 18 year age ) ; [ i.e . &gt; = 20 year age Japan ] ) Measurable disease accordance RECIST version 1.1 Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 A female subject eligible participate pregnant , breastfeeding , least one follow condition applies : Not woman childbearing potential define Appendix VIII OR A woman childbearing potential agrees use highly effective contraception ( i.e. , method failure rate le 1 % per year ) detail Appendix VII protocol 2 week start first dose study treatment , treatment period least 4 week last dose study treatment . Women childbearing potential must negative pregnancy test ( Î²HCG test serum ) prior enrollment . A male subject must agree use female partner childbearing potential use highly effective contraception ( i.e. , method failure rate le 1 % per year ) detail Appendix VII protocol first dose study treatment , treatment period least 3 month last dose study treatment refrain donate sperm period . Male subject always use barrier method condom concomitantly . Subjects characterize Epidermal Growth Factor Receptor ( EGFR ) ( documented result ; local test acceptable ) predict sensitivity EGFRtherapy , include , limited exon 19 deletion exon 21 alteration Subjects characterize Anaplastic Lymphoma Kinase ( ALK ) rearrangement ( documented result ; local test acceptable ) Active brain metastasis ( define neurologically stable le ( &lt; ) 4 week and/or symptomatic and/or require treatment steroid and/or leptomeningeal disease ) Subjects must complete prior treatment brain metastasis &gt; = 4 week prior start therapy ( &gt; = 2 week stereotactic radiosurgery/gamma knife ) . Subjects neurologically stable symptomatic therapy anticonvulsant low drug interaction risk whose steroid taper eligible . Asymptomatic untreated brain metastasis less equal ( &lt; = ) 1 cm eligible Any unresolved toxicity Grade 2 accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) previous anticancer therapy Need transfusion within 14 day prior first dose trial treatment Prior chemotherapy , biological therapy , radiation therapy , investigational anticancer therapy ( include palliative radiotherapy focal site ) within 21 day prior first dose trial treatment Subjects brain metastasis measureable lesion Inadequate hematological , liver , renal , cardiac function Prior treatment agent target HGF/cMet pathway Past current history neoplasm Nonsmall Cell Lung Cancer ( NSCLC ) , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix , cancer curatively treat evidence disease least 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>lung</keyword>
	<keyword>neoplasm</keyword>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>MET exon 14</keyword>
	<keyword>METex14</keyword>
	<keyword>pulmonary</keyword>
	<keyword>stage III</keyword>
	<keyword>stage IV</keyword>
	<keyword>c-Met</keyword>
	<keyword>cMET</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>